Objective: To evaluate the associated factors for within-day and day-to-day glycemic variability (GV) in type 2 diabetes(T2D) patients. Methods: A total of 183 hospitalized patients with T2D receiving insulin therapy were enrolled. Continuous glucose monitoring (CGM) was performed in all the subjects. The within-day GV was evaluated by using mean amplitude of glycemic excursion(MAGE), and day-to-day GV by absolute means of daily differences (MODD). Genera-lized linear model was used to estimate associated factors for within-day and day-to-day glycemic variability. Results: CGM revealed that mean MAGE and MODD were（4.75±0.91） mmol/L and （2.62±0.76） mmol/L, respectively. For within-day glycemic variability, family history of diabetes, lower levels of C-peptide, uric acid, HDL-C were independent related factors for increase of MAGE. For day-to-day glycemic variability, duration of diabetes, glycosylated hemoglobin, aspartate aminotransferase(AST) and high density lipoprotein cholesterol （HDL-C） were positively correlated with MODD, while C-peptide and premixed insulin injection were negatively correlated with MODD. Conclusions: Family history of diabetes, duration of diabetes, HbA1c, AST, HDL-C, serum levels of C-peptide, premixed insulin injection, history of CVD and serum concentration of uric acid are significantly associated with GV parameters, which indicates that the function of pancreatic beta cells and insulin sensitivity may influence the glycemic variability in type 2 diabetes patients. Premixed insulin injection may exert a better curative effect on blood glucose control in Chinese type 2 diabetes patients.
LIN Ruhai, WU Xiaohong, JIANG Zhengrong, YANG Xinna, ZHUANG Duanrong, WU Lizhen.
. Associated factors for within-day and day-to-day glycemic variability in type 2 diabetes patients[J]. Journal of Diagnostics Concepts & Practice, 2017
, 16(05)
: 516
-521
.
DOI: 10.16150/j.1671-2870.2017.05.012
[1] Stratton IM, Adler AI, Neil HA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J]. BMJ,2000,321(7258):405-412.
[2] Ceriello A.Postprandial hyperglycemia and diabetes complications: is it time to treat?[J]. Diabetes,2005,54(1):1-7.
[3] O'Sullivan EP, Dinneen SF. Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years[J]. Evid Based Med,2009, 14(1):9-10.
[4] Monnier L, Mas E, Ginet C, et al.Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes[J]. JAMA,2006,295(14):1681-1687.
[5] Brownlee M, Hirsch IB.Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications[J]. JAMA,2006,295(14):1707-1708.
[6] Bergenstal RM.Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers![J]. Diabetes Care,2015,38(8):1615-1621.
[7] del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes[J]. Diabetes,2002,51(Suppl 1):S109-S116.
[8] Service FJ, Nelson RL.Characteristics of glycemic stabi-lity[J]. Diabetes Care,1980,3(1):58-62.
[9] Kohnert KD, Augstein P, Zander E, et al.Glycemic varia-bility correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents[J]. Diabetes Care,2009,32(6):1058-1062.
[10] Jin SM, Kim TH, Bae JC, et al.Clinical factors associa-ted with absolute and relative measures of glycemic va-riability determined by continuous glucose monitoring: an analysis of 480 subjects[J]. Diabetes Res Clin Pract,2014,104(2):266-272.
[11] 周健, 贾伟平. 血糖稳定性的意义及临床评估[J]. 中华医学杂志,2006,92(30):2154-2157.
[12] 刘晓峰, 刘纯. 当前几种动态血糖监测系统的比较[J]. 国际内分泌代谢杂志,2009,29(3):197-200.
[13] Service FJ.Glucose variability[J]. Diabetes,2013,62(5):1398-1404.
[14] de Vries JH. Glucose variability: where it is important and how to measure it[J]. Diabetes,2013,62(5):1405-1408.
[15] Service FJ, Molnar GD, Rosevear JW, et al.Mean amplitude of glycemic excursions, a measure of diabetic instability[J]. Diabetes,1970,19(9):644-655.
[16] Greven WL, Beulens JW, Biesma DH, et al.Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study[J]. Diabetes Technol Ther,2010,12(9):695-699.
[17] Murata GH, Duckworth WC, Shah JH, et al.Sources of glucose variability in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study(DOVES)[J]. Clin Endocrinol (Oxf),2004,60(4):451-456.
[18] Gjesing AP, Pedersen O.'Omics'-driven discoveries in prevention and treatment of type 2 diabetes[J]. Eur J Clin Invest,2012,42(6):579-588.
[19] Xu M, Huang Y, Xie L, et al.Diabetes and Risk of Arterial Stiffness: A Mendelian Randomization Analysis[J]. Diabetes,2016,65(6):1731-1740.
[20] Chen J, Wildman RP, Hamm LL, et al.Association between inflammation and insulin resistance in U.S. nondia-betic adults: results from the Third National Health and Nutrition Examination Survey[J]. Diabetes Care,2004,27(12):2960-2965.
[21] Avula NR, Shenoy D. Evaluation of Association of Hyperuricaemia with Metabolic Syndrome and Insulin Resistance[J]. J Clin Diagn Res,2016,10(12):OC32-OC34.
[22] 王天怡, 敖虎山. 非体外循环冠状动脉旁路移植术术中血糖波动与术后高血糖的关系[J]. 安徽医学,2017, 38(7):877-880.
[23] Zhang Y, Lee ET, Howard BV, et al.Insulin resistance, incident cardiovascular diseases, and decreased kidney function among nondiabetic American Indians: the Strong Heart Study[J]. Diabetes Care,2013,36(10):3195-3200.
